Pelthos Therapeutics Inc. has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance Corporation. The initial funding of $30 million was provided at closing, with an additional $20 million available upon achieving certain milestones. The loan carries an interest rate of Prime plus 3.75% (currently 10.50%), with a term of sixty months and interest-only payments until amortization begins at month thirty-six, or month forty-eight if specific milestones are met. In connection with the financing, Pelthos issued Horizon warrants to purchase 65,488 shares of its common stock at an exercise price of $27.49 per share. The proceeds will support the commercialization of ZELSUVMI™, the launch of Xepi® and Xeglyze®, and general corporate purposes. The funding is described as minimally dilutive, with most capital raised being non-dilutive to existing shareholders except for the warrants issued. Oppenheimer & Co. served as financial advisor, with Morgan, Lewis & Bockius LLP and Sullivan & Worcester LLP as legal advisors to Pelthos. Holland & Knight LLP advised Horizon.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-26-000097), on January 13, 2026, and is solely responsible for the information contained therein.